Shares of pSivida Corp. (NASDAQ:PSDV) were up 6.6% during trading on Friday . The stock traded as high as $1.14 and last traded at $1.13. Approximately 888,161 shares were traded during trading, an increase of 74% from the average daily volume of 509,551 shares. The stock had previously closed at $1.06.

Several analysts have commented on PSDV shares. B. Riley set a $5.00 target price on shares of pSivida and gave the company a “buy” rating in a research report on Monday, December 4th. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of pSivida in a research report on Wednesday, November 8th. Laidlaw started coverage on shares of pSivida in a research report on Wednesday, November 8th. They set a “buy” rating and a $5.00 target price for the company. Northland Securities restated a “buy” rating and issued a $10.00 price objective on shares of pSivida in a research report on Monday. Finally, ValuEngine cut shares of pSivida from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $7.57.

pSivida (NASDAQ:PSDV) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.15) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.15). pSivida had a negative net margin of 226.31% and a negative return on equity of 139.56%. The business had revenue of $0.39 million during the quarter, compared to analysts’ expectations of $0.74 million. equities research analysts expect that pSivida Corp. will post -0.58 EPS for the current year.

A hedge fund recently bought a new stake in pSivida stock. OxFORD Asset Management LLP bought a new position in shares of pSivida Corp. (NASDAQ:PSDV) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned approximately 0.18% of pSivida at the end of the most recent quarter. 9.70% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “pSivida (PSDV) Trading Up 6.6%” was posted by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.watchlistnews.com/psivida-psdv-trading-up-6-6/1766766.html.

About pSivida

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.